Institutional shares held 286 Million
3.28M calls
3.16M puts
Total value of holdings $1.45B
$16.6M calls
$16M puts
Market Cap $926M
180,480,000 Shares Out.
Institutional ownership 158.3%
# of Institutions 365


Latest Institutional Activity in RXRX

Top Purchases

Q1 2025
Ubs Asset Management Americas Inc Shares Held: 6.41M ($32.9M)
Q1 2025
Ubs Group Ag Shares Held: 5.57M ($28.6M)
Q1 2025
Ark Investment Management LLC Shares Held: 34.8M ($179M)
Q1 2025
Morgan Stanley Shares Held: 5.01M ($25.7M)
Q1 2025
Nuveen, LLC Shares Held: 1.91M ($9.81M)

Top Sells

Q1 2025
Vanguard Group Inc Shares Held: 32.3M ($166M)
Q1 2025
Laurion Capital Management LP Shares Held: 1.55M ($7.94M)
Q1 2025
Goldman Sachs Group Inc Shares Held: 1.5M ($7.67M)
Q1 2025
Two Sigma Investments, LP Shares Held: 1.15M ($5.91M)
Q1 2025
Nikko Asset Management Americas, Inc. Shares Held: 8.41M ($43.1M)

About RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.


Insider Transactions at RXRX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
2.89M Shares
From 14 Insiders
Grant, award, or other acquisition 2.01M shares
Conversion of derivative security 430K shares
Exercise of conversion of derivative security 448K shares
Sell / Disposition
1.16M Shares
From 11 Insiders
Open market or private sale 857K shares
Payment of exercise price or tax liability 281K shares
Bona fide gift 25K shares

Track Institutional and Insider Activities on RXRX

Follow RECURSION PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX